You are here: Industry Insights > Novartis

News List

BDI - Novartis partnership is announced firstwordpharma
January 21, 2019
Novartis today announced a five-year collaboration with the Big Data Institute (BDI) to establish a world-leading research alliance that will improve drug development by making it more efficient and more targeted.
Novartis and Oxford University begin R&D tie-up pharmaphorum
January 21, 2019
Novartis and Oxford University have begun a partnership that will attempt to use artificial intelligence to predict how patients will respond to new and existing treatments for inflammatory diseases such as multiple sclerosis (MS) and psoriasis.
Novartis migraine drug not cost effective: UK price watchdog expressbpd
January 14, 2019
Novartis, which pledged to work with NICE to address outstanding questions, said patients would lack new treatment options if the decision remains unchanged
NICE declines to endorse Novartis’ pricey migraine drug Aimovig pharmaceutical-technology
January 14, 2019
National Institute for Health and Care Excellence (NICE) in the UK has rejected Novartis’ migraine prevention drug Aimovig (erenumab) saying the drug is not a cost-effective use of the NHS resources.....
Novartis puts AI on the job to help reps say the right things to the right doctors fiercepharma
January 13, 2019
Amid far more meetings with digital companies at the J.P. Morgan Healthcare Conference this year, Novartis’ pharma CEO Paul Hudson said he expects 2019 to be the “beginning of the tech disruption” for pharma, in everything from marketing to supply chain.
NICE draft guidance rejects use of Novartis' CGRP inhibitor Aimovig for preventing migraine firstwordpharma
January 10, 2019
The National Institute for Health and Care Excellence issued draft guidance Thursday recommending against routine NHS use of Novartis' Aimovig (erenumab) for preventing migraine. The agency determined that the injectable CGRP receptor antagonist, which co
NICE draft guidance rejects use of Novartis' CGRP inhibitor Aimovig for preventing migraine firstwordpharma
January 10, 2019
The National Institute for Health and Care Excellence issued draft guidance Thursday recommending against routine NHS use of Novartis' Aimovig (erenumab) for preventing migraine. The agency determined that the injectable CGRP receptor antagonist, which co
FDA grants breakthrough therapy status to crizanlizumab pharmaceutical-technology
January 10, 2019
Novartis has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for the use of crizanlizumab (SEG101) to prevent vaso-occlusive crises (VOCs) in sickle cell disease (SCD) patients of all genotypes.
NICE rejects Novartis’ migraine prevention drug Aimovig pharmaphorum
January 10, 2019
Some migraine sufferers in the UK hoping to get access to Novartis’ new migraine prevention drug Aimovig are facing disappointment after NICE rejected it in draft guidance.
FDA grants breakthrough therapy status for Novartis' crizanlizumab to prevent vaso-occlusive crises in sickle cell disease firstwordpharma
January 09, 2019
Novartis announced Tuesday that the FDA granted crizanlizumab a breakthrough therapy designation for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease (SCD). Samit Hirawat, head of oncology global drug de

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page